Capricor Therapeutics, Inc.
NASDAQ:CAPR
5.12 (USD) • At close September 18, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Capricor Therapeutics, Inc. |
Symbool | CAPR |
Munteenheid | USD |
Prijs | 5.12 |
Beurswaarde | 166,599,168 |
Dividendpercentage | 0% |
52-weken bereik | 2.68 - 7.28 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Linda Marbán Ph.D. |
Website | https://www.capricor.com |
An error occurred while fetching data.
Over Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)